Glow-in-the-Dark dye could replace radioactive tracer in breast cancer surgery

NCT ID NCT07441733

Recruiting now Knowledge-focused Sponsor: Casa di Cura Dott. Pederzoli Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether a fluorescent dye called indocyanine green (ICG) can effectively identify sentinel lymph nodes in breast cancer patients, potentially replacing the standard radioactive tracer. Forty women with early-stage breast cancer will receive both methods, and doctors will compare how often each finds the nodes. If ICG works as well, it could simplify the procedure and avoid radioactivity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Indocyanine Green (ICG)
What this could lead to: If successful, this could replace the standard radioactive tracer with a safer, more accessible dye for sentinel lymph node biopsy in breast cancer.
What could go wrong: This is a small pilot study (40 participants) at a single hospital, so results may not apply broadly. ICG may not identify nodes as reliably as the current method.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Ospedale P. Pederzoli Casa di Cura Privata S.p.A.
RECRUITING

Peschiera del Garda, Verona, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.